The global narcolepsy drugs market is poised for robust growth in the coming years, with the forecast period from 2021 to 2026 showing promising signs of substantial revenue expansion. Fairfield Market Research predicts an impressive Compound Annual Growth Rate (CAGR) of 11.2%, propelling the market value from US$3875.1 million in 2021 to an estimated US$6588.0 million by 2026.
Narcolepsy, a neurological condition affecting approximately one in every 2000 individuals in the U.S., brings with it a slew of challenges, including cataplexy–a sudden loss of muscle strength leading to slurred speech and affected body movements. Such symptoms hinder patients from performing optimally in both workplace and social settings. Alarmingly, Narcolepsy UK reports that at least 25,000 people in the UK suffer from narcolepsy, with a staggering 75% going undiagnosed.
The pressing need for narcolepsy patients to lead relatively normal lives has sparked a growing demand for narcolepsy drugs. Symptoms like excessive daytime sleepiness (EDS), automatic behaviors, cataplexy, hallucinations, and sleep paralysis result in a dysfunctional lifestyle, which underscores the importance of effective drug therapies. Unfortunately, narcolepsy often goes undiagnosed for many patients, emphasizing the urgency for early detection and treatment.
Narcolepsy is now recognized as a frequent disorder, ranking as the second leading cause of EDS after sleep apnea. Epidemiological studies indicate an incidence rate of 0.2 to 1.6 per thousand across European countries, Japan, and the U.S.–figures that are comparable to the prevalence of Multiple Sclerosis. These statistics underscore the pressing need for more effective treatments and heightened awareness of narcolepsy.
Recent years have witnessed a surge in narcolepsy awareness, largely driven by patient advocacy groups and welfare associations such as Narcolepsy Network Inc., European Narcolepsy Network, American Sleep Association, and Wake Up Narcolepsy. This concerted effort to raise awareness is a significant factor contributing to the growth of the global narcolepsy drugs market.
Narcolepsy Drugs Market Dominated by Narcolepsy with Cataplexy
Narcolepsy is categorized into two main types based on the presence of cataplexy: type 1, narcolepsy with cataplexy, and type 2, narcolepsy without cataplexy. Cataplexy, though rarely the initial symptom, is the definitive diagnostic criterion for narcolepsy. Type 1 narcolepsy is expected to capture a substantial 68% market share by 2026. Meanwhile, type 2 narcolepsy is the fastest-growing segment, with an impressive 11.9% CAGR during the forecast period, driven by increased public awareness of the disease.
Sodium Oxybate and Selective Serotonin Drugs Promising for Narcolepsy Patients
While there is no cure for narcolepsy, drug therapies play a crucial role in enhancing patients quality of life. Two approved drug classes for narcolepsy treatment include stimulants like modafinil and amodafinil, as well as antidepressants and tricyclics, and selective serotonin drugs, which encompass noradrenergic reuptake inhibitors and sodium oxybate.
Sodium oxybate, marketed as Xyrem, holds a prominent position in narcolepsy treatment. It is FDA-approved for treating cataplexy and associated EDS and has been recommended as the gold standard by the American Academy of Sleep Medicine. Furthermore, manufacturers offer assistance programs for uninsured patients, with sodium oxybate projected to contribute approximately 52% to the global narcolepsy drugs market in 2021.
Research Activities Drive Innovation in Narcolepsy Treatment
Research on narcolepsy is actively supported by organizations such as the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and other research facilities. Studies are aimed at uncovering genetic and environmental factors contributing to narcolepsy, with ongoing research into the basic biology of sleep, including the brain mechanisms regulating REM sleep and other sleep behaviors.
Regional Market Dynamics
Currently, North America leads the global narcolepsy drugs market with a robust CAGR of 11.3% anticipated between 2021 and 2026. Europe closely follows, with an increasing prevalence of sleep-related disorders linked to the H1N1 influenza pandemic. Asia Pacific is expected to witness significant growth, driven by rising cases of shift-work sleep disorder, increased stress levels, and improved healthcare reimbursement policies.
Key Market Players Focus on R&D and Collaborations
Prominent companies in the narcolepsy drugs market are actively exploring collaborative opportunities to strengthen their positions. Recent acquisitions, such as Takedas acquisition of Provigil from Shire, highlight the industrys commitment to advancing narcolepsy treatment. Additionally, companies are supporting patients through assistance programs, offering co-pays, and providing free products for eligible patients.
Leading players in the global narcolepsy drugs market include Harmony Biosciences, Avadel Pharmaceuticals plc, Axsome Therapeutics, Inc., Arena Pharmaceuticals, Inc., GrayMark Healthcare Inc., Teva Pharmaceutical Industries Ltd., Shionogi Inc., and Ligand Pharmaceuticals, Inc.
The global narcolepsy drugs market is poised for substantial growth, driven by increased awareness, early detection efforts, and the ongoing commitment of healthcare providers and pharmaceutical companies to improve the lives of narcolepsy patients.
Narcolepsy Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021-2026 – [2023 UPDATE Available – Forecast 2023-2030*] (By Therapeutics, By Narcolepsy Type, By Geography, Leading Companies) https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market
Our Trending Reports:
Thin Film Drugs Market
https://www.fairfieldmarketresearch.com/report/thin-film-drugs-market
Antipsychotic Drugs Market
https://www.fairfieldmarketresearch.com/report/antipsychotic-drugs-market
Antifungal Drugs Market
https://www.fairfieldmarketresearch.com/report/antifungal-drugs-market
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_440910101/2840/2023-09-25T13:12:29